Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in
treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy
. Patients disqualified from radical therapy . The total number of patients was estimated for
32.
Phase:
Phase 2
Details
Lead Sponsor:
Maria Sklodowska-Curie Institute - Oncology Center